CJC-1295 (No DAC) 10mg
CJC-1295 (No DAC) 10mg — for in vitro laboratory research use only.
Product Overview
CJC-1295 (No DAC) is a pharmaceutical-grade research compound supplied as a lyophilized powder. Each batch undergoes independent third-party testing with a Certificate of Analysis (COA) available on request.
Specifications
| CAS Number | 863288-34-0 |
| Molecular Formula | C152H252N44O42 |
| Molar Weight | ~3367.9 g/mol |
| Sequence | Modified 29-amino-acid GHRH(1-29) analog (without the Drug Affinity Complex / DAC modification) |
| Classification | Synthetic growth-hormone-releasing hormone (GHRH) analog fragment |
| Appearance | White to off-white lyophilised powder (typical presentation) |
| Solubility | Soluble in sterile water or bacteriostatic water |
| Storage | Store lyophilised powder desiccated and protected from light at -20°C. Once reconstituted, store at 2-8°C for short-term use and avoid repeated freeze-thaw cycles. |
| Shelf Life | Typically stable for up to 24 months when stored lyophilised, desiccated, and protected from light at -20°C — confirm against the specific batch's Certificate of Analysis. |
Description & Mechanism of Action
CJC-1295 (No DAC), also known as Modified GRF 1-29, is a 29-amino-acid analog of growth-hormone-releasing hormone (GHRH) engineered with amino acid substitutions for improved stability against enzymatic degradation, but without the Drug Affinity Complex (DAC) modification that allows the related long-acting variant to bind serum albumin and remain active for days. Without DAC, this version acts through the same GHRH-receptor pathway on pituitary somatotrophs — stimulating pulsatile growth hormone release — but with a much shorter half-life, requiring more frequent dosing in research protocols than the DAC-modified form. Because it shares its receptor pathway with other GHRH analogs such as tesamorelin, it is frequently studied as a reference compound for GHRH-receptor pharmacology, and is often compared alongside ghrelin-receptor agonists such as ipamorelin, which stimulate GH release through a separate, complementary pathway.
Applications in Research
- Studying GHRH-receptor-mediated pituitary signalling
- Comparative pharmacokinetic research (short-acting versus DAC-modified long-acting GHRH analogs)
- GH/IGF-1 axis research alongside ghrelin-receptor agonists
- Reference compound in growth-hormone secretagogue comparison studies
Handling, Reconstitution & Stability
- Handle as a hygroscopic powder; open vials and weigh under dry conditions where possible
- Reconstitute with sterile water or bacteriostatic water, adding solvent slowly down the side of the vial
- Swirl gently to dissolve — avoid vigorous shaking
- Filter-sterilise (e.g. 0.22 µm) immediately before use if required by your protocol
- Aliquot reconstituted solution and store at -20°C or below; avoid repeated freeze-thaw cycles
Precautions & Notes
- CAS number listings vary between suppliers for this specific ("No DAC") variant — confirm against your product's Certificate of Analysis
- The main published human pharmacokinetic study (Teichman et al., 2006) describes the long-acting, DAC-modified variant, not this No-DAC form, which has a substantially shorter half-life
- Experimental effects are concentration-, duration-, and model-dependent
- For laboratory research use only — not for human or veterinary use
This product is supplied for in vitro research purposes only. It is not intended for human or animal administration, diagnostic use, or any other purpose. Handle in accordance with good laboratory practice guidelines.